Lillian Sun

University of Pennsylvania — United States

Medicine · Health Sciences

7h-index630citations18works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(9), CAR-T cell therapy research(6), interferon and immune responses(6), Immunotherapy and Immune Responses(4), Immune Cell Function and Interaction(3)

Publications18 total

Skin immunity during pregnancy
The Journal of Immunology·2023Open Access
Maternal immune regulation of lactogenesis
The Journal of Immunology·2023Open Access
Supplementary Data from Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
2023Open Access
Supplementary Data from Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
2023Open Access
Data from Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
2023Open Access
Data from Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
2023Open Access
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas
Scientific Reports·2021· 4 citedOpen Access
Abstract 5175: Birinapant enhances death agonist antibody against TRAILR2 anti-tumor activity in HPV-positive head and neck squamous cell carcinomas
Cancer Research·2020
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
Clinical Cancer Research·2019· 78 citedOpen Access
Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition
OncoImmunology·2019· 43 citedOpen Access
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
JCI Insight·2019· 228 citedOpen Access
WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy
OncoImmunology·2018· 56 citedOpen Access
Abstract 3974: Combination of birinapant and TRAILR2 agonist antibody enhances cell death in HPV-positive head and neck squamous cell carcinomas
Cancer Research·2018
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
Journal for ImmunoTherapy of Cancer·2018· 49 citedOpen Access
Abstract 34: Wee1 inhibition sensitizes tumor cells with variable antigenicity to T cell mediated lysis
Clinical Cancer Research·2017· 1 cited
Nanocomplex-based <i>TP53</i> gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms
OncoImmunology·2017· 28 citedOpen Access
PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation
OncoImmunology·2017· 143 citedOpen Access
Abstract 1061: Modulation of death pathways by TRAILR2 agonist antibody and NF-κB pathway by NIK inhibitor in HPV-positive head and neck squamous cell carcinomas
Cancer Research·2017

Frequent Co-authors

Jay Friedman(12), Clint Allen(12), Carter Van Waes(11), Paúl E. Clavijo(10), Ellen Moore(10), Yvette Robbins(7), Megan V. Morisada(7), James W. Hodge(7), Sarah Greene(6), Paul Zolkind(5), Wojciech K. Mydlarz(5), Nicole C. Schmitt(5), Hans Schreiber(5), Ravindra Uppaluri(5), Yi An(4), Adeeb Derakhshan(4), Carter Van Waes(4), Zhong Chen(3), Christopher Silvin(3), Sophie G. Carlson(3)